Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Muhammed Bahaddin Durak has a total of 414 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Radar Based Systems Design and Optimization for Biomedical Applications

    by Şahin Yıldız, Muhammed Bahaddin Kurt

    Radar-based systems have great potential for interpreting motion-based objects using the Doppler effect. In recent years, various radar-based studies have been conducted to characterize movement-indexed vital signs, tissues, and organs. In this study, it is aimed to develop a radar system for biomedical applications. The radar system is created by combining various components. These components consist of antenna, modulator, microwave and low-pass filter circuit. Antennas are important components of the radar system. Antennas have been optimized with geometric changes. The operating frequency of the antennas has been increased from 2.36 GHz to 2.40 GHz. Radar antenna gain has been improved by increasing from 3.02 dB to 3.67 dB. The return loss has been increased from -19 dB to -28 dB. An analog-digital converter is used in the radar system for traceability of the signal reflected from the target. A moving object was placed in front of the radar system and the signals reflected from the target were monitored. It was observed that the signal amplitude was between 3 and 3.4 during the time-period when the target object was far away from the system. In close-range measurement, it was observed that the signal amplitude was between 2.8 and 3.8. It was concluded that these movements can be interpreted in biomedical applications with signal processing techniques.

  • Comparison of Performances of Two Different Antipodal Vivaldi Antennas in Microwave Breast Cancer Detection Systems

    by Şahin Yıldız, Muhammed Bahaddin Kurt

    In this study, two different antipodal Vivaldi antennas were designed using CST MWS simulation program. The proposed antipodal Vivaldi antennas were designed using 1.6 mm thick FR4 material. The dielectric constant of this material is 4.4 and the loss tangent value is 0.002. The impedance of the feed port is 50 Ω and the copper thickness is 0.035 µm. The compact size of the first antenna is 30 mm x 36 mm, its gain is 5.04 dB and its directivity is 6.48 dB. The size of the second antenna is 38 mm x 33.5 mm, its gain is 7.68 dB and its directivity is 8.77 dB. In the simulation environment, two phantoms were created by placing spherical tumors with two different diameters, each inside a separate heterogeneous breast phantom. Then, the designed antennas in the simulation environment were tested for tumor detection performance on the phantom using the radar-based microwave breast cancer imaging technique (RMWI). After the signal processing stages, tumor images were obtained. In microwave imaging methods, the performance of two different antennas on tumor detection was observed in terms of gain and directivity. In the breast cancer detection study using RMWI technique, the importance of antenna properties such as gain and directivity was emphasized.


  • Open Access

    Male predominance in inflammatory bowel disease despite similar disease activity: A large retrospective cohort study

    by Ali Atay, Mucahit Ergul, Oguz Ozturk, Kadir Can Acun, Yavuz Cagir, Muhammed Bahaddin Durak, Ilhami Yuksel

    Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease (CD), exhibit clinical heterogeneity, with sex-related differences potentially influencing disease course and prognosis. This study investigates the impact of sex on IBD prognosis in a large cohort. Data were collected from patients diagnosed with IBD at our clinics between July 1993 and April 2025. Demographic, clinical, and treatment variables were analyzed, focusing on sex-based differences in disease onset, disease activity, extraintestinal manifestations (EIMs), treatment escalation, hospitalizations, and surgical interventions. A total of 1774 patients diagnosed with IBD were included in the study. A male predominance (61%) was observed in IBD, with higher male-to-female ratios in both ulcerative colitis (1.6:1) and CD (1.47:1). Female patients presented earlier with IBD (mean age 34.7 vs 37.0 years; P = .001) and had a higher frequency of EIMs, particularly peripheral arthritis and erythema nodosum ( P < .001). No significant sex differences were observed in disease severity, hospitalizations, or need for treatment escalation. However, female patients with CD demonstrated higher disease activity at baseline, as measured by the Crohn’s disease activity index. Both sexes exhibited similar rates of biologic therapy use, the number of biologic therapies, hospitalizations, and major surgeries. Despite the male predominance in IBD prevalence, sex-related differences in clinical outcomes were minimal, with both sexes experiencing comparable disease activity, treatment escalation, and need for surgery. However, female patients exhibited a higher frequency of EIMs, highlighting the importance of a sex-based approach in clinical management.


  • Open Access

    Gastroenteroloji Textbook - Cilt (1-2)

    by Alper Macif, Ahmed Ramiz Baykan, Gökhan Çoban, Sadık Yavuz, Berk Bas, Mehmet Kasım Aydın, Selçuk Candan, Fatih Güzelbulut, Atilla Bulur, Fatih Ensaroğlu, et al.

  • Open Access

    Pankreas Fizyolojisi

    by Muhammed Bahaddin Durak, Yavuz Çağır, Taylan Metin

    Pankreas, gıda alımına sekonder olarak sindirim enzimleri, pankreas sıvısı ve bikarbonat salgılar. Pankreatik sıvıdaki enzim içeriğinin tamamı pankreas bezlerindeki asinüs yapıları tarafından sekrete edilmesine rağmen pankreas sıvısının diğer önemli bileşenlerinden bikarbonat ve su, temelde asinüslerden çıkan kanal ve kanalcıklara ait epitel hücrelerinden sekrete edilirler. Temelde ekzokrin pankreas üç temel hücreden oluşur: Asiner, duktal ve stellat. Bunlardan duktal hücreler pankreas sıvısının iyonik içeriğini değiştirir ve pankreatik sıvıdaki bikarbonat içeriğinin ana kısmını sekrete eder. Pankreatik sekresyon, bir bağırsak-beyin ekseni ve intrapankreatik sistemden oluşan enterik sinir sistemi tarafından düzenlenir. İnsülinin hücre içindeki etkisi, insülin reseptörlerine bağlanmasıyla başlar. Kan akımı yoluyla insülinin ulaştığı ilk önemli organ karaciğer olup burada etkisini temelde anabolizmayı uyarmak ve katabolizmayı inhibe etmek olarak iki şekilde gösterir. Glukoz taşıyıcı proteinler kolaylaştırılmış difüzyon mekanizmasıyla çalışır. İnsülin aksine glukagon sekresyonu glukoz ile inhibe olmaktadır. GLP-1, hem insülin salınımını arttırmak hem de glukagonun salınımını inhibe etmek gibi iki yönlü etkiler gösterirken, GLP-2 genellikle insülin salınımını artırır ancak glukagon üzerinde karmaşık etkiler gösterir.

  • Performance Evaluation of Gastroenterology Specific Language Model GastroGPT on Hepatocellular Carcinoma Management

    by Cem Şimşek, Mete Üçdal, Yiğit Yazarkan, Muhammed Bahaddin Durak, Hatice Yasemin Balaban

  • Open Access

    Three-Decade Analysis of Inflammatory Bowel Disease in Türkiye: A Multicenter Study (1993-2024)

    by Muhammed Bahaddin Durak, Yasir Furkan Cagin, Ayhan Balkan, Yusuf Coskun, Tarkan Karakan, Yavuz Cagir, Yavuz Beyazit, Ali Atay, Ali Can Erdem, Guray Can, et al.

    Background/Aims: Inflammatory bowel diseases (IBDs) are increasingly prevalent and challenging globally. Data regarding IBD frequency and severity between Europe and Asia are needed. The aim was to investigate the trend of IBD in Türkiye during the last 3 decades. Materials and Methods: The study was conducted retrospectively at 14 centers in Türkiye between June 1993 and March 2024. Results: Over 30 years, 4308 patients, of whom 2507 (58.2%) had ulcerative colitis (UC) and 1717 (39.9%) had Crohn’s Disease (CD), were included in the study. The overall median age at the onset of IBD was 34.43 (25.28-45.64) years; the age at onset of IBD was younger in CD compared to UC (32.72 vs. 35.52 years respectively, P < .001). The peak age onset range was 28-32 years in CD, whereas 23-27 years in UC. Overall, 2526 (58.6%) patients were male. The most common location was left-sided colitis in UC patients (45.1%), followed by extensive colitis (31.2%), and proctitis (23.7%), while ileal involvement in CD patients (45.2%), afterward ileocolonic (409%), and colonic (13.5%). Both illnesses are becoming increasingly prevalent. The UC/CD ratio tends to decrease over time. During the study period, 1577 (36.6%) patients received biologic treatment. During the study period, 418 (24.3%) underwent resective surgery for CD and 88 (3.5%) total colectomy for UC; the major abdominal surgery has declined over time. Conclusion: The frequency and characteristic features of IBD in Türkiye appear to be between Europe and Asia. Over time, while the usage of biologic therapy and the rate of CD have increased, the frequency of surgery has decreased. Cite this article as: Durak MB, Cagin YF, Balkan A, et al. Three-decade analysis of inflammatory bowel disease in Türkiye: A multicenter study (1993-2024). Turk J Gastroenterol. 2025;36(12):822-833.


  • Effect of periampullary diverticulum morphology on ERCP cannulation and clinical results

    by Yavuz Cagir, Muhammed Bahaddin Durak, Cem Simsek, Ilhami Yuksel

    Periampullary diverticulum (PAD) is a common anatomical variant that can potentially impact the technical difficulty and outcomes of endoscopic retrograde cholangiopancreatography (ERCP), necessitating a comprehensive understanding of its effects on the procedure. To evaluate the effect of PAD subtypes and diameter on ERCP cannulation success and clinical outcomes. The study included patients with PAD and papilla-naïve patients undergoing ERCP for suspected common bile duct stones or distal benign strictures (due to PAD compression). PAD subtyping was based on Lobo and Li-Tanaka classifications. Diverticulum size was categorized as small (<1 cm), medium (1-2 cm), and giant (≥2 cm). Of the 907 patients analyzed, 164 (18%) had PAD with a median age of 63 years. PAD patients were significantly older than non-PAD patients and had more comorbidities . The most frequent PAD type was 2B (34.1%) based on the Li-Tanaka classification. Subgroup analysis of PAD types 1, 2, 3, and 4 showed no statistically significant differences in cannulation time, success, total procedure time, or adverse events (AEs). . Overall cannulation success rates were similar between PAD and non-PAD groups (99.4% vs 99.6%). Analysis based on diverticulum size revealed higher probabilities of giant stones and procedure-related AEs in giant diverticula. The risk of post-ERCP pancreatitis was notably low at 1.8% in the PAD group. Diverticulum size, rather than PAD subtype, may be more closely associated with cannulation success and procedure-related AEs in ERCP. Individualized management considering diverticulum size may improve outcomes in PAD patients undergoing ERCP.


  • Endoscopic circumferential stricturotomy for rectal strictures in patients with Crohn's disease – A video vignette

    by Ilhami Yuksel, Ali Atay, Muhammed Bahaddin Durak, Yavuz Cagir, Mucahit Ergul, Oguz Ozturk


  • Open Access

    Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment

    by Ali Atay, Yavuz Cagir, Mucahit Ergul, Oguz Ozturk, Muhammed Bahaddin Durak, Ilhami Yuksel

    Background/Objectives: Dose escalation has been commonly used to achieve and maintain response. We aimed to compare the outcomes of adalimumab or infliximab dose escalation in inflammatory bowel disease (IBD) patients. Methods: Treatment persistence (TP) and predictive factors for remission-free treatment discontinuation (r-fTD) were evaluated in patients treated with adalimumab or infliximab dose escalation between 2019 and 2024. Results: Dose escalation was identified in 142 patients treated with adalimumab (UC: 23.9%; CD: 76.1%) and in 126 patients treated with infliximab (UC: 23.8%; CD: 76.2%). The TP rate was significantly lower in the adalimumab group (35.2%) than the infliximab group (53.2%) (p = 0.003). The survival analysis showed that drug persistence was lower in the adalimumab group compared with the infliximab group (mean time: 74.3 vs. 99.5 months, p < 0.001). TP rates showed no significant differences between UC and CD for both adalimumab (mean time UC: 64.7 months vs. CD: 76.2 months, p = 0.403) and infliximab (mean time UC: 80.3 months and CD: 102.6 months, p = 0.151). The r-fTD rates were significantly higher in the adalimumab group (62.7%) than the infliximab group (39.7%) (p < 0.001). Primary lack of response and secondary loss of response (sLOR) rates were both higher in the adalimumab group (7.7% and 51.4%) than the infliximab group (1.6% and 28.6%). However, serious adverse events were lower in the adalimumab group (2.1%) than the infliximab group (7.9%) (p = 0.027). Conclusions: Infliximab dose escalation was more effective than adalimumab in both UC and CD patients. Regarding the side effect profile, adalimumab dose escalation was found to be safer compared with infliximab.